Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease

Paolo Spallarossa, Piefranco Rossettin, Francesco Minuto, Davide Caruso, Renzo Cordera, Micaela Battistini, Antonina Barreca, Maria Augusta Masperone, Claudio Brunelli

Research output: Contribution to journalArticlepeer-review

Abstract

We have examined the effects of 6 months of treatment with growth hormone (GH) (0.02 U/kg/day) in 10 patients with chronic postischemic cardiac failure. Ten patients matched for age, body mass index, functional class, and ejection fraction served as a control group. In the GH group, 1 patient died and 2 were withdrawn from the study because of arrhythmia or worsening of heart failure. In the control group, 1 patient died and 1 patient was withdrawn from the study because of progressive heart failure. Among GH patients, those with an unfavorable outcome had a greater left ventricular end-diastolic diameter (79, 82, and 88 mm) on entry to the study than patients without adverse events (range 62 to 72 mm). At the end of the study, the seven GH patients reported a feeling of well-being and had a significant increase in their exercise test duration (462 ± 121 vs 591 ± 105 seconds, p

Original languageEnglish
Pages (from-to)430-433
Number of pages4
JournalThe American Journal of Cardiology
Volume84
Issue number4
DOIs
Publication statusPublished - Aug 15 1999

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease'. Together they form a unique fingerprint.

Cite this